- Atomoxetine (Strattera®)
- Citalopram (Celexa®)
- Coenzyme Q-10 - PREQUEL
- Creatine - PRECREST
- Ethyl-EPA (Miraxion)
- Memantine (Namenda®)
- Minocycline (Minocin®)
- Tetrabenazine (Nitoman®, Xenazine®)
Clinical Trial Background by Huntington Study Group (HSG)
Clinical Trial Background by NIH ClinicalTrials.gov
List of Clinical Trials by NIH ClinicalTrials.gov
Trial information at NIH ClincalTrials.gov (European trial)
Trial information at NIH ClincalTrials.gov (North American trial)
Trial status: The Phase III trial in Europe and the Phase II trial in the U.S. have been completed.
Trial results: The European Trial (MermaHD), and the North American (HART) trial had very similar results. The larger dosage showed improvement in voluntary motor scores, and a greater improvement in total motor scores. Though this is a positive signal for benefit in Huntington's, the degree of improvement in the primary endpoint (voluntary motor measures) was not sufficient for drug approval by the FDA, or by the European Medicine Agency (EMA), the regulatory agency for granting drug approval in Europe. Another Phase 3 trial will be needed.